title: The microtubule inhibiting agent epothilone B antagonizes glioma cell motility associated with reorganization of the actin-binding protein α-actinin 4.
abstract: Invasion of normal brain tissue by brain tumor cells is a major contributing factor to the recurrence and resistance of clinically diagnosed glioblastomas to therapy (surgery, chemotherapy, radiation). Here, we have assessed the efficacy of the microtubule inhibiting agent epothilone B on glioblastoma cell motility, a prerequisite cellular program of invasive glioblastomas. Using cell migration assays and immunofluorescence techniques we demonstrated that epothilone B abrogated glioblastoma cell motility as a consequence of α-actinin 4 redistristrubiton and the breakdown of cellular structures (leading edge, stress fibers) it is associated with during cell migration. Evaluation of the microtubule actin cross linking factor in glioblastoma cells also revealed epothilone B invoked changes in this cytoskeleton cross linking protein, resembling α-actinin 4 changes in response to epothilone B. We have demonstrated in this study that epothilone B antagonizes glioblastoma cell motility due to the disruption of cytoskeleton binding proteins that aide in preserving the structural organization of the cytoskeleton filamentous network. Furthermore, we provide preclincial evidence that epothilone B effects on glioblastomas are not limited to the impairment of dividing tumors cells but that it also targets migratory and invasive glioblastoma cells, suggesting that this agent has potential clinical benefit due to its ability to target divergent cellular programs in the glioblastoma tumor mass.
authors.affiliation: Department of Biological Sciences, Grambling State University, Central and Main, Grambling, LA 71245, USA.
authors.forename: Whitney I
authors.initials: WI
authors.lastname: Henry
authors.forename: Juwen
authors.initials: J
authors.lastname: Dubois
authors.forename: Quincy A
authors.initials: QA
authors.lastname: Quick
mesh_terms: D000185:Actinin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology*; D002465:Cell Movement / Q000187:drug effects*; D015536:Down-Regulation; D004353:Drug Evaluation, Preclinical; D034261:Epothilones / Q000494:pharmacology*; D005910:Glioma / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D008840:Microfilament Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D008870:Microtubules / Q000187:drug effects / Q000378:metabolism; D055503:Protein Multimerization / Q000187:drug effects; D021381:Protein Transport / Q000187:drug effects; D050257:Tubulin Modulators / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: C111453:ACTN4 protein, human; D000970:Antineoplastic Agents; D034261:Epothilones; D008840:Microfilament Proteins; D050257:Tubulin Modulators; D000185:Actinin; C093788:epothilone B